News › Clinical Practice, Industry News, Patient Care

Promising Phase 2 Data of CCH for Cellulite Published

March 28, 2019

Phase 2 data of Endo International’s collagenase clostridium histolyticum (CCH) for the treatment of cellulite, published in Dermatologic Surgery (February 28, 2019), demonstrate that CCH delivered clinically meaningful and statistically significant improvement as compared to placebo for all primary and secondary endpoints.
The Phase 2 clinical trial enrolled 375 women aged 18 years or older (mean age 46.5), who were randomized to receive up to three treatment sessions of CCH (0.84 mg/session, n=189) or placebo (n=186), with each treatment session occurring approximately 21 days apart. Twelve injections were administered into cellulite dimples during each session across an entire treatment area (left or right buttock, or left or right posterior thigh).Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available